Diabetic nephropathy and retinopathy

Medical Clinics of North America

Volumn 88, Issue 4, 2004, Pages 1001-1036

  Jawa, Ali ^a   Kcomt, Juanita ^a   Fonseca, Vivian A ^a  

^a TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE REDUCTASE; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; HYDROGEN; IRBESARTAN; LISINOPRIL; LITHIUM; LOSARTAN; METFORMIN; PRORENIN; PROTEIN KINASE C; RAMIPRIL; RUBOXISTAURIN; SODIUM; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; APOPTOSIS; AUTOFLUORESCENCE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; COMORBIDITY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; CYTOKINE RELEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE DURATION; DOPPLER FLOWMETRY; DRUG EFFICACY; ETHNIC DIFFERENCE; GENETIC SUSCEPTIBILITY; GENOTYPE; GLOMERULUS FILTRATION RATE; GLYCOSYLATION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY HYPERTROPHY; KIDNEY INJURY; LABORATORY TEST; LASER COAGULATION; MICROALBUMINURIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERICYTE; PREDICTION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; PROTEINURIA; RAMAN SPECTROMETRY; RETINA DETACHMENT; RETINA MACULA EDEMA; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; UREA NITROGEN BLOOD LEVEL; VITRECTOMY;

AGE DISTRIBUTION; AGED; BIOPSY, NEEDLE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INCIDENCE; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 4143126849     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2004.04.012     Document Type: Review

References (170)

1. Skyler J.S. Microvascular complications: retinopathy and nephropathy. Endocrinol Metab Clin North Am. 30:2001;833-856
2. Prevent Blindness America. R&B legend Gladys Knight sings praises of early detection and management of diabetes. 2003;Prevent Blindness America, Schaumberg (IL)
3. Allen A.C. So called intercapillary glomerulosclerosis, a lesion associated with diabetes mellitus. Arch Pathol. 32:1941;33-51
4. Bell E.T. Renal lesions in diabetes mellitus. Am J Pathol. 18:1942;744-745
5. Bell E.T. Renal diseases. 1946;Henry Kimpton Publishers, London
6. Kimmelstiel P. Studies on renal biopsy specimens with the aid of electron microscopy 1. Glomeruli in diabetes. Am J Clin Pathol. 38:1962;270-279
7. The Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. Arch Ophthalmol. 97:1979;654-655
8. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 103:1985;1796-1806
9. The Diabetic Retinopathy Vitrectomy Study Research Group. Two-year course of visual acuity in severe proliferative diabetic retinopathy with conventional management. Diabetic Retinopathy Vitrectomy Study (DRVS) report number 1. Ophthalmology. 92:1985;492-502
10. Klein R., Klein B.E., Moss S.E., Davis M.D., DeMets D.L. The Wisconsin epidemiologic study of diabetic retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol. 102:1984;520-526
11. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 44:1995;968-983
12. Ohkubo Y., Kishikawa H., Araki E., Miyata T., Isami S., Motoyoshi S., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 28:1995;103-117
13. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 317:1998;703-713
14. Reichard P., Nilsson B.Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 329:1993;304-309
15. Hypertension in Diabetes Study (HDS). I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens. 11:1993;309-317
16. Chaturvedi N., Sjolie A.K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 351:1998;28-31
17. Ismail N., Becker B., Strzelczyk P., Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int. 55:1999;1-28
18. Orchard T.J., Dorman J.S., Maser R.E., Becker D.J., Drash A.L., Ellis D., et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 39:1990;1116-1124
19. Parving H.H., Hommel E., Mathiesen E., Skott P., Edsberg B., Bahnsen M., et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. BMJ. 296:1988;156-160
20. Nelson R.G., Knowler W.C., Pettitt D.J., Saad M.F., Bennett P.H. Diabetic kidney disease in Pima Indians. Diabetes Care. 16:1993;335-341
21. Bojestig M., Arnqvist H.J., Hermansson G., Karlberg B.E., Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med. 330:1994;15-28
22. Rossing P., Rossing K., Jacobsen P., Parving H.H. Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes. 44:1995;739-743
23. Klein R. Vision disorders in diabetes. Diabetes in America. 1995;293 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda
24. Mogensen C.E., Christensen C.K., Vittinghus E. The stages in diabetic renal disease, with emphasis on the stage of incipient diabetic nephropathy. Diabetes. 32:(Suppl 2):1983;64-78
25. Mogensen C.E., Andersen M.J. Increased kidney size and glomerular filtration rate in untreated juvenile diabetes: normalization by insulin-treatment. Diabetologia. 11:1975;221-224
26. Kroustrup J.P., Gundersen H.J., Osterby R. Glomerular size and structure in diabetes mellitus III. Early enlargement of the capillary surface. Diabetologia. 13:1977;207-210
27. Hostetter T.H., Rennke H.G., Brenner B.M. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 72:1982;375-380
28. Mogensen C.E., Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med. 311:1984;89-93
29. Osterby R., Gundersen H.J. Glomerular size and structure in diabetes mellitus I. Early abnormalities. Diabetologia. 11:1975;225-229
30. Schober E., Pollak A., Coradello H., Lubec G. Glycosylation of glomerular basement membrane in type 1 (insulin-dependent) diabetic children. Diabetologia. 23:1982;485-487
31. Cohen M.P., Wu V.Y., Surma M.L. Non-collagen protein and proteoglycan in renal glomerular basement membrane. Biochim Biophys Acta. 678:1981;322-328
32. Vigstrup J., Mogensen C.E. Proliferative diabetic retinopathy: at risk patients identified by early detection of microalbuminuria. Acta Ophthalmol. 63:1985;530-534
33. Mogensen C.E. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int. 31:1987;673-689
34. Mogensen C.E., Hansen K.W., Osterby R., Damsgaard E.M. Blood pressure elevation versus abnormal albuminuria in the genesis and prediction of renal disease in diabetes. Diabetes Care. 15:1992;1192-1204
35. Mogensen C.E. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ. 285:1982;685-688
36. Fioretto P., Steffes M.W., Brown D.M., Mauer S.M. An overview of renal pathology in insulin-dependent diabetes mellitus in relationship to altered glomerular hemodynamics. Am J Kidney Dis. 20:1992;549-558
37. Harris R.D., Steffes M.W., Bilous R.W., Sutherland D.E., Mauer S.M. Global glomerular sclerosis and glomerular arteriolar hyalinosis in insulin dependent diabetes. Kidney Int. 40:1991;107-114
38. Heilig C.W., Concepcion L.A., Riser B.L., Freytag S.O., Zhu M., Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest. 96:1995;1802-1814
39. Chakrabarti S., Cukiernik M., Hileeto D., Evans T., Chen S. Role of vasoactive factors in the pathogenesis of early changes in diabetic retinopathy. Diabetes Metab Res Rev. 16:2000;393-407
40. Hammes H.P., Du X., Edelstein D., Taguchi T., Matsumura T., Ju Q., et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med. 9:2003;294-299
41. Neely K.A., Quillen D.A., Schachat A.P., Gardner T.W., Blankenship G.W. Diabetic retinopathy. Med Clin North Am. 82:1998;847-876
42. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 414:2001;813-820
43. Way K.J., Katai N., King G.L. Protein kinase C and the development of diabetic vascular complications. Diabet Med. 18:2001;945-959
44. Li W., Yanoff M., Liu X., Ye X. Retinal capillary pericyte apoptosis in early human diabetic retinopathy. Chin Med J (Engl). 110:1997;659-663
45. Mizutani M., Kern T.S., Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest. 97:1996;2883-2890
46. Meister A., Anderson M.E. Glutathione. Annu Rev Biochem. 52:1983;711-760
47. Li W., Liu X., Yanoff M., Cohen S., Ye X. Cultured retinal capillary pericytes die by apoptosis after an abrupt fluctuation from high to low glucose levels: a comparative study with retinal capillary endothelial cells. Diabetologia. 39:1996;537-547
48. Heilig C.W., Concepcion L.A., Riser B.L., Freytag S.O., Zhu M., Cortes P. Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose milieu mimics the diabetic phenotype. J Clin Invest. 96:1995;1802-1814
49. De Vriese A.S., Tilton R.G., Elger M., Stephan C.C., Kriz W., Lameire N.H. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 12:2001;993-1000
50. Utimura R., Fujihara C.K., Mattar A.L., Malheiros D.M., De L.N., Zatz R. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 63:2003;209-216
51. Wolf G. Molecular mechanisms of renal hypertrophy: role of p27Kip1. Kidney Int. 56:1999;1262-1265
52. Sharma K., Ziyadeh F.N. Hyperglycemia and diabetic kidney disease: the case for transforming growth factor-beta as a key mediator. Diabetes. 44:1995;1139-1146
53. Border W.A., Noble N.A. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int. 54:1998;1390-1391
54. Sharma K., Eltayeb B.O., McGowan T.A., Dunn S.R., Alzahabi B., Rohde R., et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis. 34:1999;818-823
55. Cooper M.E. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 352:1998;213-219
56. Craven P.A., DeRubertis F.R. Protein kinase C is activated in glomeruli from streptozotocin diabetic rats: possible mediation by glucose. J Clin Invest. 83:1989;1667-1675
57. Chen S., Cohen M.P., Lautenslager G.T., Shearman C.W., Ziyadeh F.N. Glycated albumin stimulates TGF-beta 1 production and protein kinase C activity in glomerular endothelial cells. Kidney Int. 59:2001;673-681
58. Koya D., King G.L. Protein kinase C activation and the development of diabetic complications. Diabetes. 47:1998;859-866
59. Koya D., Jirousek M.R., Lin Y.W., Ishii H., Kuboki K., King G.L. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest. 100:1997;115-126
60. Koya D., Lee I.K., Ishii H., Kanoh H., King G.L. Prevention of glomerular dysfunction in diabetic rats by treatment with d-alpha-tocopherol. J Am Soc Nephrol. 8:1997;426-435
61. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science. 272:1996;728-731
62. Frank R.N. The aldose reductase controversy. Diabetes. 43:1994;169-172
63. Whiteside C.I., Thompson J. The role of angiotensin-II in progressive diabetic glomerulopathy in the rat. Endocrinology. 125:1989;1932-1940
64. Alzaid A.A., Dinneen S.F., Melton L.J. III, Rizza R.A. The role of growth hormone in the development of diabetic retinopathy. Diabetes Care. 17:1994;531-534
65. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 331:1994;1480-1487
66. Mitamura Y., Tashimo A., Nakamura Y., Tagawa H., Ohtsuka K., Mizue Y., et al. Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Diabetes Care. 25:2002;2352
67. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853
68. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986
69. Writing Team for Diabetes Control and Complications Trial/Epidemiology of Diabetic Intervensions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 287:2002;2563-2569
70. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care. 22:1999;99-111
71. American Diabetes Association. Diabetic retinopathy. Diabetes Care. 23:(Suppl 1):2000;S73-S76
72. Klein R., Klein B.E., Moss S.E. Epidemiology of proliferative diabetic retinopathy. Diabetes Care. 15:1992;1875-1891
73. Estacio R.O., Jeffers B.W., Gifford N., Schrier R.W. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care. 23:(Suppl 2):2000;B54-B64
74. Parving H.H., Osterby R., Ritz E. Diabetic nephropathy. Brenner B.M. The kidney. 2000;1731 Saunders, Philadelphia: WB
75. Cambien F., Poirier O., Lecerf L., Evans A., Cambou J.P., Arveiler D., et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 359:1992;641-644
76. Yoshida H., Kuriyama S., Atsumi Y., Tomonari H., Mitarai T., Hamaguchi A., et al. Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int. 50:1996;657-664
77. Schmidt S., Ritz E. Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant. 12:(Suppl 2):1997;37-41
78. Schmidt S., Strojek K., Grzeszczak W., Bergis K., Ritz E. Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant. 12:1997;427-429
79. Pettitt D.J., Saad M.F., Bennett P.H., Nelson R.G., Knowler W.C. Familial predisposition to renal disease in two generations of Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia. 33:1990;438-443
80. Satko S.G., Langefeld C.D., Daeihagh P., Bowden D.W., Rich S.S., Freedman B.I. Nephropathy in siblings of African Americans with overt type 2 diabetic nephropathy. Am J Kidney Dis. 40:2002;489-494
81. Trevisan R., Viberti G. Genetic factors in the development of diabetic nephropathy. J Lab Clin Med. 126:1995;342-349
82. Jeffers B.W., Estacio R.O., Raynolds M.V., Schrier R.W. Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy. Kidney Int. 52:1997;473-477
83. Kuramoto N., Iizuka T., Ito H., Yagui K., Omura M., Nozaki O., et al. Effect of ACE gene on diabetic nephropathy in NIDDM patients with insulin resistance. Am J Kidney Dis. 33:1999;276-281
84. Kunz R., Bork J.P., Fritsche L., Ringel J., Sharma A.M. Association between the angiotensin-converting enzyme-insertion/deletion polymorphism and diabetic nephropathy: a methodologic appraisal and systematic review. J Am Soc Nephrol. 9:1998;1653-1663
85. Shah V.O., Scavini M., Nikolic J., Sun Y., Vai S., Griffith J.K., et al. Z-2 microsatellite allele is linked to increased expression of the aldose reductase gene in diabetic nephropathy. J Clin Endocrinol Metab. 83:1998;2886-2891
86. Ritz E., Orth S.R. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 341:1999;1127-1133
87. Earle K., Viberti G.C. Familial, hemodynamic and metabolic factors in the predisposition to diabetic kidney disease. Kidney Int. 45:1994;434-437
88. Barzilay J., Warram J.H., Bak M., Laffel L.M., Canessa M., Krolewski A.S. Predisposition to hypertension: risk factor for nephropathy and hypertension in IDDM. Kidney Int. 41:1992;723-730
89. Trevisan R., Fioretto P., Barbosa J., Mauer M. Insulin-dependent diabetic sibling pairs are concordant for sodium-hydrogen antiport activity. Kidney Int. 55:1999;2383-2389
90. Rudberg S., Persson B., Dahlquist G. Increased glomerular filtration rate as a predictor of diabetic nephropathy: an 8-year prospective study. Kidney Int. 41:1992;822-828
91. Mogensen C.E. Prediction of clinical diabetic nephropathy in IDDM patients: alternatives to microalbuminuria? Diabetes. 39:1990;761-767
92. Tuttle K.R., Bruton J.L., Perusek M.C., Lancaster J.L., Kopp D.T., DeFronzo R.A. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med. 324:1991;1626-1632
93. Vora J.P., Dolben J., Dean J.D., Thomas D., Williams J.D., Owens D.R., et al. Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus. Kidney Int. 41:1992;829-835
94. Nowack R., Raum E., Blum W., Ritz E. Renal hemodynamics in recent-onset type II diabetes. Am J Kidney Dis. 20:1992;342-347
95. Gambara V., Mecca G., Remuzzi G., Bertani T. Heterogeneous nature of renal lesions in type II diabetes. J Am Soc Nephrol. 3:1993;1458-1466
96. Smith S.R., Svetkey L.P., Dennis V.W. Racial differences in the incidence and progression of renal diseases. Kidney Int. 40:1991;815-822
97. Brancati F.L., Whittle J.C., Whelton P.K., Seidler A.J., Klag M.J. The excess incidence of diabetic end-stage renal disease among blacks: a population-based study of potential explanatory factors. JAMA. 268:1992;3079-3084
98. Kohler K.A., McClellan W.M., Ziemer D.C., Kleinbaum D.G., Boring J.R. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis. 36:2000;903-913
99. Chaiken R.L., Palmisano J., Norton M.E., Banerji M.A., Bard M., Sachimechi I., et al. Interaction of hypertension and diabetes on renal function in black NIDDM subjects. Kidney Int. 47:1995;1697-1702
100. Ng L.L., Davies J.E., Siczkowski M., Sweeney F.P., Quinn P.A., Krolewski B., et al. Abnormal Na + /H + antiporter phenotype and turnover of immortalized lymphoblasts from type 1 diabetic patients with nephropathy. J Clin Invest. 93:1994;2750-2757
101. The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med. 134:2001;370-379
102. American Diabetes Association. Diabetic nephropathy. Diabetes Care. 23:(Suppl 1):2000;S69-S72
103. Parving H.H., Gall M.A., Skott P., Jorgensen H.E., Lokkegaard H., Jorgensen F., et al. Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int. 41:1992;758-762
104. Christensen P.K., Larsen S., Horn T., Olsen S., Parving H.H. Causes of albuminuria in patients with type 2 diabetes without diabetic retinopathy. Kidney Int. 58:2000;1719-1731
105. Rosenn B., Miodovnik M., Kranias G., Khoury J., Combs C.A., Mimouni F., et al. Progression of diabetic retinopathy in pregnancy: association with hypertension in pregnancy. Am J Obstet Gynecol. 166:1992;1214-1218
106. Mazzucco G., Bertani T., Fortunato M., Bernardi M., Leutner M., Boldorini R., et al. Different patterns of renal damage in type 2 diabetes mellitus: a multicentric study on 393 biopsies. Am J Kidney Dis. 39:2002;713-720
107. Kasinath B.S., Mujais S.K., Spargo B.H., Katz A.I. Nondiabetic renal disease in patients with diabetes mellitus. Am J Med. 75:1983;613-617
108. Furuta T., Seino J., Saito T., Sato H., Agatsuma J., Ootaka T., et al. Insulin deposits in membranous nephropathy associated with diabetes mellitus. Clin Nephrol. 37:1992;65-69
109. Gans R.O., Ueda Y., Ito S., Kohli R., Min I., Shafi M., et al. The occurrence of IgA-nephropathy in patients with diabetes mellitus may not be coincidental: a report of five cases. Am J Kidney Dis. 20:1992;255-260
110. Padilla B., Weiss M., Kant K.S. Henoch-Schönlein purpura in a patient with diabetic nephropathy: case report and a review of the literature. Am J Kidney Dis. 20:1992;191-194
111. Mak S.K., Gwi E., Chan K.W., Wong P.N., Lo K.Y., Lee K.F., et al. Clinical predictors of non-diabetic renal disease in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant. 12:1997;2588-2591
112. Matsumae T., Fukusaki M., Sakata N., Takebayashi S., Naito S. Thin glomerular basement membrane in diabetic patients with urinary abnormalities. Clin Nephrol. 42:1994;221-226
113. Olsen S. Identification of non-diabetic glomerular disease in renal biopsies from diabetics: a dilemma. Nephrol Dial Transplant. 14:1999;1846-1849
114. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 26:(Suppl 1):2003;S33-S50
115. Sussman E.J., Tsiaras W.G., Soper K.A. Diagnosis of diabetic eye disease. JAMA. 247:1982;3231-3234
116. Sebag J., Ansari R.R., Dunker S., Suh K.I. Dynamic light scattering of diabetic vitreopathy. Diabetes Technol Ther. 1:1999;169-176
117. Katz A., Kruger E.F., Minko G., Liu C.H., Rosen R.B., Alfano R.R. Detection of glutamate in the eye by Raman spectroscopy. J Biomed Opt. 8:2003;167-172
118. Van Schaik H.J., Coppens J., Van den Berg T.J., Van Best J.A. Autofluorescence distribution along the corneal axis in diabetic and healthy humans. Exp Eye Res. 69:1999;505-510
119. Michelson G., Welzenbach J., Pal I., Harazny J. Functional imaging of the retinal microvasculature by scanning laser Doppler flowmetry. Int Ophthalmol. 23:2001;327-335
120. Gomez-Ulla F., Fernandez M.I., Gonzalez F., Rey P., Rodriguez M., Rodriguez-Cid M.J., et al. Digital retinal images and teleophthalmology for detecting and grading diabetic retinopathy. Diabetes Care. 25:2002;1384-1389
121. Borch-Johnsen K., Feldt-Rasmussen B., Strandgaard S., Schroll M., Jensen J.S. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol. 19:1999;1992-1997
122. Deckert T., Kofoed-Enevoldsen A., Norgaard K., Borch-Johnsen K., Feldt-Rasmussen B., Jensen T. Microalbuminuria: implications for micro- and macrovascular disease. Diabetes Care. 15:1992;1181-1191
123. Gerstein H.C., Mann J.F., Yi Q., Zinman B., Dinneen S.F., Hoogwerf B., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 286:2001;421-426
124. Spoelstra-de Man A.M., Brouwer C.B., Stehouwer C.D., Smulders Y.M. Rapid progression of albumin excretion is an independent predictor of cardiovascular mortality in patients with type 2 diabetes and microalbuminuria. Diabetes Care. 24:2001;2097-2101
125. Tuttle K.R., Puhlman M.E., Cooney S.K., Short R. Urinary albumin and insulin as predictors of coronary artery disease: an angiographic study. Am J Kidney Dis. 34:1999;918-925
126. Winocour P.H., Harland J.O., Millar J.P., Laker M.F., Alberti K.G. Microalbuminuria and associated cardiovascular risk factors in the community. Atherosclerosis. 93:1992;71-81
127. Mykkanen L., Zaccaro D.J., Wagenknecht L.E., Robbins D.C., Gabriel M., Haffner S.M. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes. 47:1998;793-800
128. Pinkney J.H., Denver A.E., Mohamed-Ali V., Foster C., Yudkin J.S. Insulin resistance in non-insulin-dependent diabetes mellitus is associated with microalbuminuria independently of ambulatory blood pressure. J Diabetes Complications. 9:1995;230-233
129. Wasada T., Katsumori K., Saeki A., Saito S., Omori Y. Urinary albumin excretion rate is related to insulin resistance in normotensive subjects with impaired glucose tolerance. Diabetes Res Clin Pract. 34:1997;157-162
130. Yudkin J.S. Hyperinsulinaemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med. 28:1996;433-438
131. Mykkanen L., Haffner S.M., Kuusisto J., Pyorala K., Laakso M. Microalbuminuria precedes the development of NIDDM. Diabetes. 43:1994;552-557
132. Krolewski A.S., Warram J.H., Rand L.I., Kahn C.R. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N Engl J Med. 317:1987;1390-1398
133. Almdal T., Norgaard K., Feldt-Rasmussen B., Deckert T. The predictive value of microalbuminuria in IDDM: a five-year follow-up study. Diabetes Care. 17:1994;120-125
134. Krolewski A.S., Laffel L.M., Krolewski M., Quinn M., Warram J.H. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 332:1995;1251-1255
135. Chaturvedi N., Bandinelli S., Mangili R., Penno G., Rottiers R.E., Fuller J.H. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 60:2001;219-227
136. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 310:1984;356-360
137. Klein R., Klein B.E., Moss S.E., Cruickshanks K.J. Ten-year incidence of gross proteinuria in people with diabetes. Diabetes. 44:1995;916-923
138. Nelson R.G., Bennett P.H., Beck G.J., Tan M., Knowler W.C., Mitch W.E., et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med. 335:1996;1636-1642
139. Ravid M., Savin H., Jutrin I., Bental T., Katz B., Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 118:1993;577-581
140. Mogensen C.E., Hansen K.W., Pedersen M.M., Christensen C.K. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care. 14:(Suppl 4):1991;13-26
141. Parving H.H., Hommel E., Jensen B.R., Hansen H.P. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int. 60:2001;228-234
142. The Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia. 39:1996;587-593
143. Viberti G., Mogensen C.E., Groop L.C., Pauls J.F. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA. 271:1994;275-279
144. Gerstein H.C. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev. 18:(Suppl 3):2002;S82-S85
145. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 329:1993;1456-1462
146. Hebert L.A., Bain R.P., Verme D., Cattran D., Whittier F.C., Tolchin N., et al. Remission of nephrotic range proteinuria in type I diabetes. Collaborative Study Group. Kidney Int. 46:1994;1688-1693
147. Kasiske B.L., Kalil R.S., Ma J.Z., Liao M., Keane W.F. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 118:1993;129-138
148. Adler A.I., Stratton I.M., Neil H.A., Yudkin J.S., Matthews D.R., Cull C.A., et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 321:2000;412-419
149. ALLHAT Officers and Coordinators for ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 288:2002;2981-2997
150. Brenner B.M., Cooper M.E., Zeeuw D.D., Grunfeld J.P., Keane W.F., Kurokawa K., et al. The losartan renal protection study: rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst. 1:2000;328-335
151. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 345:2001;861-869
152. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. Ugeskr Laeger. 163:2001;5519-5524
153. Mogensen C.E., Neldam S., Tikkanen I., Oren S., Viskoper R., Watts R.W., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ. 321:2000;1440-1444
154. Tatti P., Pahor M., Byington R.P., Di Mauro P., Guarisco R., Strollo G., et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 21:1998;597-603
155. Levinsky N.G. Specialist evaluation in chronic kidney disease: too little, too late. Ann Intern Med. 137:2002;542-543
156. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Ophthalmology. 98:(Suppl 5):1991;757-765
157. The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol. 108:1990;1577-1583
158. Shinoda K., Ishida S., Kawashima S., Wakabayashi T., Uchita M., Matsuzaki T., et al. Clinical factors related to the aqueous levels of vascular endothelial growth factor and hepatocyte growth factor in proliferative diabetic retinopathy. Curr Eye Res. 21:2000;655-661
159. Stefansson E., Machemer R., de Juan E. Jr., McCuen B.W., Peterson J. Retinal oxygenation and laser treatment in patients with diabetic retinopathy. Am J Ophthalmol. 113:1992;36-38
160. Marshall J., Mellerio J. Laser irradiation of retinal tissue. Brit Med Bull. 26:(2):1970;156-160
161. Reddy V.M., Zamora R.L., Olk R.J. Quantitation of retinal ablation in proliferative diabetic retinopathy. Am J Ophthalmol. 119:1995;760-766
162. Doft B.H., Metz D.J., Kelsey S.F. Augmentation laser for proliferative diabetic retinopathy that fails to respond to initial panretinal photocoagulation. Ophthalmology. 99:1992;1728-1734
163. Patz A., Schatz H., Berkow J.W., Gittelsohn A.M., Ticho U. Macular edema: an overlooked complication of diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol. 77:1973;OP34-OP42
164. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline. ETDRS report no. 19. Arch Ophthalmol. 113:1995;1144-1155
165. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 98:(Suppl 5):1991;766-785
166. Striph G.G., Hart W.M. Jr., Olk R.J. Modified grid laser photocoagulation for diabetic macular edema: the effect on the central visual field. Ophthalmology. 95:1988;1673-1679
167. Ferris F.L. III, Podgor M.J., Davis M.D. Macular edema in diabetic retinopathy study patients. Diabetic Retinopathy Study Report number 12. Ophthalmology. 94:1987;754-760
168. Pender P.M., Benson W.E., Compton H., Cox G.B. The effects of panretinal photocoagulation on dark adaptation in diabetics with proliferative retinopathy. Ophthalmology. 88:1981;635-638
169. Machemer R., Parel J.M., Buettner H. A new concept for vitreous surgery I. Instrumentation. Am J Ophthalmol. 73:1972;1-7
170. Lewis H., Abrams G.W., Blumenkranz M.S., Campo R.V. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology. 99:1992;753-759